Condition
CD20-positive B-cell Non-Hodgkin Lymphoma
Total Trials
2
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Part 1 Cohort 3
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Phase 1 (2)
Trial Status
Active Not Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT05395533Phase 1Active Not RecruitingPrimary
A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.
NCT01569750Phase 1CompletedPrimary
A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
Showing all 2 trials
Research Network
Common Treatments
- Part 1 Cohort 31
- Part 1 Cohort 11
- Part 1 Cohort 21
- Part 2 Cohort 21
- Part 2 Cohort 11
Active Sponsors
- Janssen Research & Development, LLC1
- Pharmacyclics LLC.1
- Zhejiang Teruisi Pharmaceutical Inc.1
Top Investigators
Cancer Institute and Hospital, Chinese Academy of Medical Sciences